These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27161090)

  • 21. Prostate cancer characteristics in a multiracial community.
    Ravery V; Dominique S; Hupertan V; Ben Rhouma S; Toublanc M; Boccon-Gibod L; Boccon-Gibod L
    Eur Urol; 2008 Mar; 53(3):533-8. PubMed ID: 17467885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
    Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
    Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.
    Patel HD; Tosoian JJ; Carter HB; Epstein JI
    JAMA Oncol; 2018 Jan; 4(1):89-92. PubMed ID: 28715578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?
    Sundi D; Ross AE; Humphreys EB; Han M; Partin AW; Carter HB; Schaeffer EM
    J Clin Oncol; 2013 Aug; 31(24):2991-7. PubMed ID: 23775960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
    Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical performance of transperineal template guided mapping biopsy for therapeutic decision making in low risk prostate cancer.
    Ahallal Y; Sanchez-Salas R; Sivaraman A; Barret E; Secin FP; Validire P; Rozet F; Galiano M; Cathelineau X
    Actas Urol Esp; 2016 Dec; 40(10):615-620. PubMed ID: 27527686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate.
    Cross CK; Shultz D; Malkowicz SB; Huang WC; Whittington R; Tomaszewski JE; Renshaw AA; Richie JP; D'Amico AV
    J Clin Oncol; 2002 Jun; 20(12):2863-8. PubMed ID: 12065563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Low Socioeconomic Status With Adverse Prostate Cancer Pathology Among African American Men Who Underwent Radical Prostatectomy.
    Weprin SA; Parker DC; Jones JD; Kaplan JR; Giusto LL; Mydlo JH; Yu SS; Lee DI; Eun DD; Reese AC
    Clin Genitourin Cancer; 2019 Oct; 17(5):e1054-e1059. PubMed ID: 31303559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Gleason score upgrading in a large African-American population.
    Vora A; Large T; Aronica J; Haynes S; Harbin A; Marchalik D; Nissim H; Lynch J; Bandi G; McGeagh K; Kowalczyk K; Ghasemian R; Venkatesan K; Verghese M; Hwang J
    Int Urol Nephrol; 2013 Oct; 45(5):1257-62. PubMed ID: 23864415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
    Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.
    Thomas C; Pfirrmann K; Pieles F; Bogumil A; Gillitzer R; Wiesner C; Thüroff JW; Melchior SW
    BJU Int; 2012 Jan; 109(2):214-9. PubMed ID: 21592293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
    Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
    Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
    Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
    BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.